{"entity":{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","aka":[],"tldr":"Saad Usmani led the pivotal teclistamab study, the first bispecific antibody approved for myeloma.","summary":"Saad Z. Usmani is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center. He is a multiple myeloma specialist known for leading MajesTEC-1, the pivotal study of teclistamab that produced the first bispecific antibody approved for myeloma, and for contributing to the daratumumab and ciltacabtagene autoleucel programmes. His selected paper reports teclistamab in relapsed or refractory multiple myeloma. He now chairs the myeloma service at MSK, working on BCMA-directed bispecific T-cell engagers and CAR-T.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/saad-usmani"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Usmani%20SZ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["t-cell-engager"],"targets":["bcma"],"drugs":["teclistamab","daratumumab"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["majestec-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Myeloma Service","institutionId":"mskcc","specialisms":["Multiple myeloma","Bispecific antibodies","CAR-T"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/saad-usmani"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Usmani%20SZ%5BAuthor%5D"}],"papers":[{"title":"Teclistamab in relapsed or refractory multiple myeloma","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203478","doi":"10.1056/NEJMoa2203478"},{"title":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","journal":"The Lancet","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CARTITUDE-1%20ciltacabtagene%20autoleucel%20Berdeja%20Lancet%202021"},{"title":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint","journal":"Nature Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEPHEUS%20daratumumab%20bortezomib%20lenalidomide%20transplant-ineligible%20Usmani%20Nature%20Medicine%202025"}],"orcid":"0000-0002-5484-8731"},"route":"/people/saad-usmani/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"drug":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/"}],"paper":[{"id":"paper-cartitude-1-cilta-cel-lancet-2021","kind":"paper","name":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","route":"/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/"},{"id":"paper-cepheus-dara-vrd-natmed-2025","kind":"paper","name":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint","route":"/key-papers/paper-cepheus-dara-vrd-natmed-2025/"}]}}